AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, Moshe, Pazarentzos, Evangelos, Juric, Dejan, Sheng, Qing, Pelossof, Raphael A., Brook, Samuel, Benzaken, Ana Oaknin, Rodon, Jordi +18 more·2015·Cancer Cell
DOI 10.1016/j.ccell.2015.03.010

Cited by (339)

Items 301–339 of 339

  1. Additional file 5 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  2. Additional file 2 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  3. Additional file 1 of Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma
    Gu, Ziyue, Shi Chaoji, Li, Jiayi, Han, Yong, Sun Bao, Zhang, Wuchang, Wu, Jing, Zhou, Guoyu, Ye, Weimin, Li, Jiang et al. · 2022 · Figshare
  4. Additional file 17 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  5. Additional file 3 of FOXO transcriptional activity is associated with response to chemoradiation in EAC
    Aafke Creemers, Amber P. van der Zalm, Anja van de Stolpe, Laurent Holtzer, Stoffels, M., Gerrit K. J. Hooijer, Eva A. Ebbing, van Ooijen, H., Anne van Brussel, Aussems-Custers, E. M. G. et al. · 2022 · Figshare
  6. Additional file 4 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  7. Additional file 18 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  8. Additional file 23 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  9. Additional file 7 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  10. Additional file 4 of FOXO transcriptional activity is associated with response to chemoradiation in EAC
    Aafke Creemers, Amber P. van der Zalm, Anja van de Stolpe, Laurent Holtzer, Stoffels, M., Gerrit K. J. Hooijer, Eva A. Ebbing, van Ooijen, H., Anne van Brussel, Aussems-Custers, E. M. G. et al. · 2022 · Figshare
  11. Additional file 25 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  12. Additional file 8 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  13. Additional file 13 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  14. Additional file 6 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  15. Additional file 1 of FOXO transcriptional activity is associated with response to chemoradiation in EAC
    Aafke Creemers, Amber P. van der Zalm, Anja van de Stolpe, Laurent Holtzer, Stoffels, M., Gerrit K. J. Hooijer, Eva A. Ebbing, van Ooijen, H., Anne van Brussel, Aussems-Custers, E. M. G. et al. · 2022 · Figshare
  16. Additional file 24 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  17. Additional file 5 of FOXO transcriptional activity is associated with response to chemoradiation in EAC
    Aafke Creemers, Amber P. van der Zalm, Anja van de Stolpe, Laurent Holtzer, Stoffels, M., Gerrit K. J. Hooijer, Eva A. Ebbing, van Ooijen, H., Anne van Brussel, Aussems-Custers, E. M. G. et al. · 2022 · Figshare
  18. Additional file 2 of FOXO transcriptional activity is associated with response to chemoradiation in EAC
    Aafke Creemers, Amber P. van der Zalm, Anja van de Stolpe, Laurent Holtzer, Stoffels, M., Gerrit K. J. Hooijer, Eva A. Ebbing, van Ooijen, H., Anne van Brussel, Aussems-Custers, E. M. G. et al. · 2022 · Figshare
  19. Additional file 19 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  20. Additional file 21 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  21. Additional file 16 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  22. Additional file 9 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  23. Additional file 14 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  24. Additional file 1 of TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma
    Kara Marie Ruicci, Jalna Meens, Paul Plantinga, Stecho, William, Nicole C. Pinto, John Yoo, Fung, Kevin, MacNeil, Danielle, Joe S. Mymryk, John W. Barrett et al. · 2020 · Figshare
  25. Additional file 22 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  26. Additional file 12 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  27. Additional file 1 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  28. Additional file 20 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  29. Additional file 3 of A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation
    Peng, Xin, Huang, Xin, Lulu, Talal Ben, Jia, Wenqing, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Chen, Xi, Liu, Shanshan et al. · 2024 · Figshare
  30. Additional file 1 of Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer
    Alberto Juan, Carmen Segrelles, Almudena del Campo-Balguerías, Bravo, Iván, Silva, Ignacio, Jorge Peral, Ocaña, Alberto, Pilar Clemente-Casares, Carlos Alonso‐Moreno, Corina Lorz · 2023 · Figshare
  31. AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma
    Rupesh Paudel, Simon G. Goller, Stefanie Schwarz, Katharina Meder, M-E Goebeler, Marc Schmidt · 2026 · Neoplasia
  32. Cartographie du phosphoprotéome régulé par les isoformes du PI3K de classe I dans le cancer du pancréas
    Célia Cintas · 2017 · theses.fr (ABES)
  33. Rôle de la surexpression des flotillines dans l'activation de voie de signalisation oncogéniques induisant la transition épithélio-mésenchymateuse
    Mallory Genest · 2019 · theses.fr (ABES)
  34. Neoplastic mast cells from patients with mastocytosis express AXL : effects on proliferation, apoptosis, and resistance to tyrosine kinase inhibitors
    Kitsada Kangboonruang · 2024 · theses.fr (ABES)
  35. Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
    Xin Cheng, Y Zhang, Changli Qian, Erica M. Holdridge, Guruprasad Ananda, Tao Jiang, Jing Ni, Shaozhen Xie, Hao Gu, Renlei Ji et al. · 2026 · Nature Communications
  36. AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer
    Marc Creixell, Scott D. Taylor, Jacqueline S. Gerritsen, Mingxuan Jiang, Song Yi Bae, Teresa Augustin, Michelle Loui, Carmen Boixo, Saki Minamino, Victoria Gong et al. · 2026 · Cell Reports
  37. AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer
    Holly L. Hoffman, Kate M. Von Handorf, Catherine A. Behrmann, Justin Durla Lathia, David R. Plas · 2026 · iScience
  38. BindingDB Entry 50013982: Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
    BindingDB · 2022 · UC San Diego
  39. BindingDB Entry 50047507: AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
    BindingDB · 2017 · UC San Diego